Melodia Therapeutics has acquired the exclusive rights to develop, manufacture, and commercialize MDI-0151, a candidate therapy for hard-to-treat ANCA-associated vasculitis (AAV) and other disorders marked by overactivation of neutrophils, a type of immune cell. Melodia said it will “rapidly initiate” investigational new drug (IND)-enabling studies in preparation of a…
News
The U.S. Food and Drug Administration (FDA) has given NovelMed the green light to initiate a Phase 2 clinical trial to test its investigational antibody-based therapy ruxoprubart in adults with ANCA-associated vasculitis (AAV). The Phase 2 study (NCT06226662) will evaluate the therapy’s safety and efficacy in up…
Inflammatory bowel disease (IBD) — a chronic disease where the bowel becomes inflamed, causing recurring lower abdominal pain and diarrhea — can overlap with ANCA-associated vasculitis (AAV) and is often diagnosed first, a study found. The finding suggests a possible link between the two diseases, and that having IBD…
Symptoms and disease manifestations of eosinophilic granulomatosis with polyangiitis (EGPA), a rare type of ANCA-associated vasculitis (AAV), are generally similar between patients with and without ANCAs, the self-reactive antibodies that drive most AAV cases. That’s according to a study analyzing data from a registry of people with vasculitis, or…
Sinonasal manifestations — those encompassing the nose and the paranasal sinuses, or the air-filled cavities around the nose — in granulomatosis with polyangiitis (GPA) vary among patients, based on disease activity and duration. That’s according to a small, retrospective study of GPA patients with sinonasal manifestations seen at a…
About 1 in every 5 people with ANCA-associated vasculitis (AAV), at some point in life, may experience problems that keep the thyroid gland from making the right amount of hormones, with these problems most often developing within five years of an AAV diagnosis, a large study found. While…
High blood levels of the protein CX3CL1, a pro-inflammatory immune signal that appears to be associated with blood vessel inflammation, can accurately discriminate microscopic polyangiitis (MPA) and granulomatosis with polyangiitis (GPA) patients with active disease from those without, a study found. Importantly, high CX3CL1 levels were found to increase the…
AstraZeneca’s Fasenra (benralizumab), which is approved for a rare type of asthma, led to clinical remission in up to 70% of eosinophilic granulomatosis with polyangiitis (EGPA) patients taking the therapy off-label in the real-world setting. The therapy was also associated with a reduced daily dose of oral…
People with ANCA-associated vasculitis (AAV) who are positive for antibodies against both myeloperoxidase (MPO) and proteinase 3 (PR3) show a combination of clinical characteristics from patients with each antibody type, according to a recent study in China. While double-positive patients are generally more similar to those with MPO-ANCAs, particularly…
Argenx has decided not to go ahead with its development plans for efgartigimod as a potential treatment for ANCA-associated vasculitis (AAV) after the therapy failed to show beneficial effects in late-stage clinical trials of two other autoimmune diseases. Efgartigimod is approved in the U.S. in two formulations for…
Recent Posts
- New model may help identify which AAV patients are at risk of blood clots
- Hidden immune activity can occur despite disease remission in AAV
- Acceptance is an ongoing practice in life with chronic illness
- Survival rate on kidney dialysis similar for those with, without AAV
- Initial data from trial of AAV therapy NKX019 expected this year